R. L. Noble, C. T. Beer, and J. H. Cutts, *, Annals of the New York Academy of Sciences, vol.45, issue.3, pp.882-94, 1958.
DOI : 10.1111/j.1749-6632.1958.tb54906.x

P. B. Schiff, J. Fant, and S. B. Horwitz, Promotion of microtubule assembly in vitro by taxol, Nature, vol.446, issue.5698, pp.665-672, 1979.
DOI : 10.1083/jcb.71.3.749

M. C. Wani, H. L. Taylor, M. E. Wall, P. Coggon, and A. Mcphail, Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia, Journal of the American Chemical Society, vol.93, issue.9, pp.2325-2332, 1971.
DOI : 10.1021/ja00738a045

B. Pajk, Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: Findings from the EORTC 10001 randomized phase II trial, The Breast, vol.17, issue.2, pp.180-185, 2008.
DOI : 10.1016/j.breast.2007.09.002

B. Norris, Phase III Comparative Study of Vinorelbine Combined With Doxorubicin Versus Doxorubicin Alone in Disseminated Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8, Journal of Clinical Oncology, vol.18, issue.12, pp.2385-94, 2000.
DOI : 10.1200/JCO.2000.18.12.2385

J. Dimitroulis and G. P. Stathopoulos, Evolution of non-small cell lung cancer chemotherapy (Review), Oncology Reports, vol.13, pp.923-953, 2005.
DOI : 10.3892/or.13.5.923

C. Gridelli, Treatment of Advanced Non???Small-Cell Lung Cancer in the Elderly: Results of an International Expert Panel, Journal of Clinical Oncology, vol.23, issue.13, pp.3125-3162, 2005.
DOI : 10.1200/JCO.2005.00.224

M. Markman, Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies, Trends in Pharmacological Sciences, vol.29, issue.10, pp.515-524, 2008.
DOI : 10.1016/j.tips.2008.07.007

M. L. Amador, J. Jimeno, L. Paz-ares, H. Cortes-funes, and M. Hidalgo, Progress in the development and acquisition of anticancer agents from marine sources, Annals of Oncology, vol.14, issue.11, pp.1607-1622, 2003.
DOI : 10.1093/annonc/mdg443

K. C. Nicolaou, Total synthesis of taxol 11. de Lemos, E. et al. Total synthesis of discodermolide: optimization of the effective synthetic route, Nature Chemistry, vol.367, issue.14, pp.630-634, 1994.

T. Busch and A. Kirschning, Recent advances in the total synthesis of pharmaceutically relevant diterpenes, Natural Product Reports, vol.120, issue.2, pp.318-359, 2008.
DOI : 10.1039/b705652b

P. A. Wender, S. G. Hegde, R. D. Hubbard, and L. Zhang, Total Synthesis of (???)-Laulimalide, Journal of the American Chemical Society, vol.124, issue.18, pp.4956-4963, 2002.
DOI : 10.1021/ja0258428

P. J. Sammak and G. G. Borisy, Direct observation of microtubule dynamics in living cells, Nature, vol.332, issue.6166, pp.724-730, 1988.
DOI : 10.1038/332724a0

J. Kelling, K. Sullivan, L. Wilson, and M. A. Jordan, Suppression of centromere dynamics by Taxol in living osteosarcoma cells, Cancer Res, vol.63, pp.2794-801, 2003.

T. Okouneva, O. Azarenko, L. Wilson, B. A. Littlefield, and M. A. Jordan, Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase, Molecular Cancer Therapeutics, vol.7, issue.7, pp.2003-2014, 2008.
DOI : 10.1158/1535-7163.MCT-08-0095

E. Hamel and D. G. Covell, Antimitotic Peptides and Depsipeptides, Current Medicinal Chemistry-Anti-Cancer Agents, vol.2, issue.1, pp.19-53, 2002.
DOI : 10.2174/1568011023354263

E. Lacey and J. Gill, Biochemistry of benzimidazole resistance, Acta Tropica, vol.56, issue.2-3, pp.245-62, 1994.
DOI : 10.1016/0001-706X(94)90066-3

O. Azarenko, T. Okouneva, K. W. Singletary, M. A. Jordan, and L. Wilson, Suppression of microtubule dynamic instability and turnover in MCF7 breast cancer cells by sulforaphane, Carcinogenesis, vol.29, issue.12, pp.2360-2368, 2008.
DOI : 10.1093/carcin/bgn241

S. Lobert, J. W. Ingram, and J. J. Correia, Additivity of dilantin and vinblastine inhibitory effects on microtubule assembly, Cancer Res, vol.59, pp.4816-4838, 1999.

R. M. Buey, Microtubule Interactions with Chemically Diverse Stabilizing Agents: Thermodynamics of Binding to the Paclitaxel Site Predicts Cytotoxicity, Chemistry & Biology, vol.12, issue.12, pp.1269-79, 2005.
DOI : 10.1016/j.chembiol.2005.09.010

E. Hamel, Synergistic Effects of Peloruside A and Laulimalide with Taxoid Site Drugs, but Not with Each Other, on Tubulin Assembly, Molecular Pharmacology, vol.70, issue.5, pp.1555-64, 2006.
DOI : 10.1124/mol.106.027847

J. T. Huzil, A Unique Mode of Microtubule Stabilization Induced by Peloruside A, Journal of Molecular Biology, vol.378, issue.5, pp.1016-1046, 2008.
DOI : 10.1016/j.jmb.2008.03.026

M. A. Jordan and K. Kamath, How Do Microtubule-Targeted Drugs Work? An Overview, Current Cancer Drug Targets, vol.7, issue.8, pp.730-772, 2007.
DOI : 10.2174/156800907783220417

J. Zhou and P. Giannakakou, Targeting Microtubules for Cancer Chemotherapy, Current Medicinal Chemistry-Anti-Cancer Agents, vol.5, issue.1, pp.65-71, 2005.
DOI : 10.2174/1568011053352569

J. R. Infante, Phase II Trial of Weekly Docetaxel, Vinorelbine, and Trastuzumab in the First-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer, Clinical Breast Cancer, vol.9, issue.1, pp.23-31, 2009.
DOI : 10.3816/CBC.2009.n.004

W. N. William and . Jr, Phase II Study of Vinorelbine and Docetaxel in the Treatment of Advanced Non???Small-Cell Lung Cancer as Frontline and Second-Line Therapy, American Journal of Clinical Oncology, 2009.
DOI : 10.1097/COC.0b013e318199fb99

G. R. Hudes, Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer., Journal of Clinical Oncology, vol.10, issue.11, pp.1754-61, 1992.
DOI : 10.1200/JCO.1992.10.11.1754

P. Giannakakou, L. Villalba, H. Li, M. Poruchynsky, and T. Fojo, Combinations of pacliataxel and vinblastine and their effects on tublin polymerization and cellular cytotoxicity: Characterization of a synergistic schedule, vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines, pp.57-63, 1997.
DOI : 10.1002/(SICI)1097-0215(19980105)75:1<57::AID-IJC10>3.0.CO;2-A

M. A. Jordan, R. J. Toso, D. Thrower, L. Wilson, and S. S. Ng, Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations., Proceedings of the National Academy of Sciences, vol.90, issue.20, pp.9552-9558, 1993.
DOI : 10.1073/pnas.90.20.9552

G. M. Tozer, C. Kanthou, and B. C. Baguley, Disrupting tumour blood vessels, Nature Reviews Cancer, vol.48, issue.8, pp.423-458, 2005.
DOI : 10.1038/sj.bjc.6690416

J. W. Lippert, Vascular disrupting agents, Bioorganic & Medicinal Chemistry, vol.15, issue.2, pp.605-620, 2007.
DOI : 10.1016/j.bmc.2006.10.020

G. G. Dark, Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature, Cancer Res, vol.57, pp.1829-1863, 1997.

J. Griggs, J. C. Metcalfe, and R. Hesketh, Targeting tumour vasculature: the development of combretastatin A4, The Lancet Oncology, vol.2, issue.2, pp.82-89, 2001.
DOI : 10.1016/S1470-2045(00)00224-2

C. Kanthou and G. M. Tozer, The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells, Blood, vol.99, issue.6, pp.2060-2069, 2002.
DOI : 10.1182/blood.V99.6.2060

G. M. Tozer, Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability, Cancer Res, vol.61, pp.6413-6435, 2001.

E. Alli, J. Bash-babula, J. M. Yang, and W. N. Hait, Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer, Cancer Res, vol.62, pp.6864-6873, 2002.

C. M. Galmarini, Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics, British Journal of Cancer, vol.88, issue.11, pp.1793-1802, 2003.
DOI : 10.1038/sj.bjc.6600960

P. Seve and C. Dumontet, Is class III ??-tubulin a predictive factor in patients receiving tubulin-binding agents?, The Lancet Oncology, vol.9, issue.2, pp.168-75, 2008.
DOI : 10.1016/S1470-2045(08)70029-9

C. Dumontet, M. A. Jordan, and F. Lee, Ixabepilone: targeting ??III-tubulin expression in taxane-resistant malignancies, Molecular Cancer Therapeutics, vol.8, issue.1, pp.17-25, 2009.
DOI : 10.1158/1535-7163.MCT-08-0986

R. Bhattacharya and F. Cabral, Molecular Basis for Class V ??-Tubulin Effects on Microtubule Assembly and Paclitaxel Resistance, Journal of Biological Chemistry, vol.284, issue.19, pp.13023-13055, 2009.
DOI : 10.1074/jbc.M900167200

M. Haber, Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance, J Biol Chem, vol.270, pp.31269-75, 1995.

M. Kavallaris, C. A. Burkhart, and S. B. Horwitz, Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol 63. Kavallaris, M. et al. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells, Br J Cancer Cancer Res, vol.80, issue.61, pp.1020-1025, 1999.

P. P. Gan, E. Pasquier, and M. Kavallaris, Class III ??-Tubulin Mediates Sensitivity to Chemotherapeutic Drugs in Non Small Cell Lung Cancer, Cancer Research, vol.67, issue.19, pp.9356-63, 2007.
DOI : 10.1158/0008-5472.CAN-07-0509

J. A. Mccarroll, P. P. Gan, M. Liu, and M. Kavallaris, ??III-Tubulin Is a Multifunctional Protein Involved in Drug Sensitivity and Tumorigenesis in Non-Small Cell Lung Cancer, Cancer Research, vol.70, issue.12, pp.4995-5003, 2010.
DOI : 10.1158/0008-5472.CAN-09-4487

G. Ferrandina, Class III ??-Tubulin Overexpression Is a Marker of Poor Clinical Outcome in Advanced Ovarian Cancer Patients, Clinical Cancer Research, vol.12, issue.9, pp.2774-2783, 2006.
DOI : 10.1158/1078-0432.CCR-05-2715

P. Giannakakou, Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant ??-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization, Journal of Biological Chemistry, vol.272, issue.27, pp.17118-17143, 1997.
DOI : 10.1074/jbc.272.27.17118

Y. Gokmen-polar, ??-Tubulin Mutations Are Associated with Resistance to 2-Methoxyestradiol in MDA-MB-435 Cancer Cells, Cancer Research, vol.65, issue.20, pp.9406-9420, 2005.
DOI : 10.1158/0008-5472.CAN-05-0088

M. Hari, Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of ??-tubulin (Asp26Glu) and less stable microtubules, Molecular Cancer Therapeutics, vol.5, issue.2, pp.270-278, 2006.
DOI : 10.1158/1535-7163.MCT-05-0190

M. Monzo, Paclitaxel Resistance in Non???Small-Cell Lung Cancer Associated With Beta-Tubulin Gene Mutations, Journal of Clinical Oncology, vol.17, issue.6, pp.1786-93, 1999.
DOI : 10.1200/JCO.1999.17.6.1786

S. Sale, Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers, Mol Cancer Ther, vol.1, pp.215-240, 2002.

S. Sale, P. J. Oefner, and B. Sikic, Re: Genetic Analysis of the beta-Tubulin Gene, TUBB, in Non-Small-Cell Lung Cancer, CancerSpectrum Knowledge Environment, vol.94, issue.10, pp.776-783, 2002.
DOI : 10.1093/jnci/94.10.776

A. F. Wahl, Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis, Nature Medicine, vol.48, issue.1, pp.72-81, 1996.
DOI : 10.1038/nm0196-72

S. Fan, B. Cherney, W. Reinhold, K. Rucker, and P. M. O-'connor, These data suggested that paclitaxel could be more active in cells which had lost normal P53 function, a common occurrence in tumor cells. 74 Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment, Clin Cancer Res, vol.4, pp.1047-54, 1998.

D. Debernardis, p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel, Cancer Res, vol.57, pp.870-874, 1997.

T. C. King, p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma, Cancer, vol.18, issue.4, pp.769-73, 2000.
DOI : 10.1002/1097-0142(20000815)89:4<769::AID-CNCR8>3.0.CO;2-6

V. Malamou-mitsi, Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy, Annals of Oncology, vol.17, issue.10, pp.1504-1515, 2006.
DOI : 10.1093/annonc/mdl147

A. R. Shoemaker, A Small-Molecule Inhibitor of Bcl-XL Potentiates the Activity of Cytotoxic Drugs In vitro and In vivo, Cancer Research, vol.66, issue.17, pp.8731-8740, 2006.
DOI : 10.1158/0008-5472.CAN-06-0367

D. R. Bublik, M. Scolz, G. Triolo, M. Monte, and C. Schneider, Human GTSE-1 Regulates p21CIP1/WAF1 Stability Conferring Resistance to Paclitaxel Treatment, Journal of Biological Chemistry, vol.285, issue.8, pp.5274-81, 2010.
DOI : 10.1074/jbc.M109.045948

N. Patel, Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells, Proceedings of the National Academy of Sciences, vol.107, issue.6, pp.2503-2511
DOI : 10.1073/pnas.0910649107

L. Huang, Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1??, Journal of Cancer Research and Clinical Oncology, vol.89, issue.3, pp.447-56
DOI : 10.1007/s00432-009-0675-4

J. A. Bauer, Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation, Clinical Cancer Research, vol.16, issue.2, pp.681-90, 2010.
DOI : 10.1158/1078-0432.CCR-09-1091

D. M. Townsend and K. D. Tew, The role of glutathione-S-transferase in anti-cancer drug resistance, Oncogene, vol.22, issue.47, pp.7369-75, 2003.
DOI : 10.1038/sj.onc.1206940

M. Zhou, MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression, Journal of Biological Chemistry, vol.285, issue.28, pp.21496-507, 2010.
DOI : 10.1074/jbc.M109.083337

Y. Fujita, MiR-148a Attenuates Paclitaxel Resistance of Hormone-refractory, Drug-resistant Prostate Cancer PC3 Cells by Regulating MSK1 Expression, Journal of Biological Chemistry, vol.285, issue.25, pp.19076-84, 2010.
DOI : 10.1074/jbc.M109.079525

J. Bellmunt, Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract, Journal of Clinical Oncology, vol.27, issue.27, pp.4454-61, 2009.
DOI : 10.1200/JCO.2008.20.5534

A. Cormier, M. Marchand, R. B. Ravelli, M. Knossow, and B. Gigant, Structural insight into the inhibition of tubulin by vinca domain peptide ligands, EMBO reports, vol.35, issue.11, pp.1101-1107, 2008.
DOI : 10.1107/S0907444900014736

J. Horti, Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer, Cancer Chemotherapy and Pharmacology, vol.21, issue.Suppl 2, pp.173-80, 2008.
DOI : 10.1007/s00280-007-0665-7

K. Tamura, Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses, Cancer Chemotherapy and Pharmacology, vol.5, issue.2, pp.285-93, 2007.
DOI : 10.1007/s00280-006-0382-7

R. L. Piekarz, Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma, Journal of Clinical Oncology, vol.27, issue.32, pp.5410-5417, 2009.
DOI : 10.1200/JCO.2008.21.6150

C. Twelves, A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane., Journal of Clinical Oncology, vol.28, issue.18_suppl, pp.7-1004, 2010.
DOI : 10.1200/jco.2010.28.18_suppl.cra1004

T. Besse-hammer, A dose-escalating study of XRP6258 in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy: Preliminary results. -ASCO, J Clin Oncol, vol.27, p.1053, 2009.

D. Sampath, MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo, Mol Cancer Ther, vol.2, pp.873-84, 2003.

J. M. Terwogt, B. Nuijen, W. W. Huinink, and J. Beijnen, Alternative formulations of paclitaxel, Cancer Treatment Reviews, vol.23, issue.2, pp.87-95, 1997.
DOI : 10.1016/S0305-7372(97)90022-0

H. Gelderblom, J. Verweij, K. Nooter, and A. Sparreboom, Cremophor EL, European Journal of Cancer, vol.37, issue.13, pp.1590-1598, 2001.
DOI : 10.1016/S0959-8049(01)00171-X

W. J. Gradishar, -Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer, Journal of Clinical Oncology, vol.27, issue.22, pp.3611-3620, 2009.
DOI : 10.1200/JCO.2008.18.5397

D. R. Shepard, Phase II Trial of Neoadjuvant Nab-Paclitaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy, The Journal of Urology, vol.181, issue.4, pp.1672-1679, 2009.
DOI : 10.1016/j.juro.2008.11.121

T. E. Stinchcombe, Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane??) on three treatment schedules in patients with solid tumors, Cancer Chemotherapy and Pharmacology, vol.20, issue.5, pp.759-66, 2007.
DOI : 10.1007/s00280-007-0423-x

M. G. Teneriello, Phase II Evaluation of Nanoparticle Albumin???Bound Paclitaxel in Platinum-Sensitive Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer, Journal of Clinical Oncology, vol.27, issue.9, pp.1426-1457, 2009.
DOI : 10.1200/JCO.2008.18.9548

T. Y. Kim, Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies, Clinical Cancer Research, vol.10, issue.11, pp.3708-3724, 2004.
DOI : 10.1158/1078-0432.CCR-03-0655

T. C. Chou, Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel, Proceedings of the National Academy of Sciences, vol.95, issue.26, pp.15798-802, 1998.
DOI : 10.1073/pnas.95.26.15798

D. Geest and K. , Phase II Clinical Trial of Ixabepilone in Patients With Recurrent or Persistent Platinum- and Taxane-Resistant Ovarian or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study, Journal of Clinical Oncology, vol.28, issue.1, pp.149-53, 2010.
DOI : 10.1200/JCO.2009.24.1455

J. J. Lee and S. M. Swain, Development of Novel Chemotherapeutic Agents to Evade the Mechanisms of Multidrug Resistance (MDR), Seminars in Oncology, vol.32, pp.22-28, 2005.
DOI : 10.1053/j.seminoncol.2005.09.013

J. Hoffmann, Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases, Neuro-Oncology, vol.11, issue.2, pp.158-66, 2009.
DOI : 10.1215/15228517-2008-072

D. Lee, Activity of Epothilone B Analogues Ixabepilone and Patupilone in Hormone-Refractory Prostate Cancer, Clinical Prostate Cancer, vol.3, issue.2, pp.80-82, 2004.
DOI : 10.1016/S1540-0352(11)70066-X

D. Arnold, Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial, British Journal of Cancer, vol.8, issue.8, pp.1241-1248, 2009.
DOI : 10.1002/cncr.20977

C. M. Galmarini, Sagopilone, a microtubule stabilizer for the potential treatment of cancer, Curr Opin Investig Drugs, vol.10, pp.1359-71, 2009.

A. Silvani, Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas, Journal of Neuro-Oncology, vol.45, issue.2, pp.61-65, 2009.
DOI : 10.1007/s11060-009-9890-8

T. M. Beer, Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel, Investigational New Drugs, vol.22, issue.14S, pp.565-70, 2007.
DOI : 10.1007/s10637-007-9068-1

G. J. Rustin, Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results, Journal of Clinical Oncology, vol.21, issue.15, pp.2815-2837, 2003.
DOI : 10.1200/JCO.2003.05.185

J. P. Stevenson, Phase I Trial of the Antivascular Agent Combretastatin A4 Phosphate on a 5-Day Schedule to Patients With Cancer: Magnetic Resonance Imaging Evidence for Altered Tumor Blood Flow, Journal of Clinical Oncology, vol.21, issue.23, pp.4428-4466, 2003.
DOI : 10.1200/JCO.2003.12.986

M. M. Cooney, Cardiovascular Safety Profile of Combretastatin A4 Phosphate in a Single-Dose Phase I Study in Patients with Advanced Cancer, Clinical Cancer Research, vol.10, issue.1, pp.96-100, 2004.
DOI : 10.1158/1078-0432.CCR-0364-3

C. J. Mooney, A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid Carcinoma and Correlation of Baseline Serum-Soluble Intracellular Adhesion Molecule-1 with Outcome, Thyroid, vol.19, issue.3, pp.233-273, 2009.
DOI : 10.1089/thy.2008.0321

P. M. Lorusso, Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors, Investigational New Drugs, vol.77, issue.2, pp.159-67, 2008.
DOI : 10.1007/s10637-008-9112-9

J. Hua, Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate, Anticancer Res, vol.23, pp.1433-1473, 2003.

A. Delmonte and C. Sessa, AVE8062: a new combretastatin derivative vascular disrupting agent, Expert Opinion on Investigational Drugs, vol.22, issue.10, pp.1541-1549, 2009.
DOI : 10.1007/s10637-008-9112-9

S. P. Anthony, Initial results of a first-in-man phase I study of EPC2407, a novel small molecule microtubule inhibitor anticancer agent with tumor vascular endothelial disrupting activity, Journal of Clinical Oncology, vol.26, issue.15_suppl, p.2531, 2008.
DOI : 10.1200/jco.2008.26.15_suppl.2531

S. D. Shnyder, P. A. Cooper, N. J. Millington, G. R. Pettit, and M. C. Bibby, Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models, International Journal of Oncology, vol.31, pp.353-60, 2007.
DOI : 10.3892/ijo.31.2.353

J. Michels, A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer, Annals of Oncology, vol.21, issue.2, pp.305-316, 2010.
DOI : 10.1093/annonc/mdp311

C. Sweeney, A Phase II Multicenter, Randomized, Double-Blind, Safety Trial Assessing the Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral 2-Methoxyestradiol Capsules in Hormone-Refractory Prostate Cancer, Clinical Cancer Research, vol.11, issue.18, pp.6625-6658, 2005.
DOI : 10.1158/1078-0432.CCR-05-0440

J. James, Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer, Investigational New Drugs, vol.57, issue.1, pp.41-49, 2007.
DOI : 10.1007/s10637-006-9008-5

S. V. Rajkumar, Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma, Clinical Cancer Research, vol.13, issue.20, pp.6162-6169, 2007.
DOI : 10.1158/1078-0432.CCR-07-0807

A. J. Tevaarwerk, Phase I Trial of 2-Methoxyestradiol NanoCrystal Dispersion in Advanced Solid Malignancies, Clinical Cancer Research, vol.15, issue.4, pp.1460-1465, 2009.
DOI : 10.1158/1078-0432.CCR-08-1599

D. Escuin, The hematopoietic-specific ??1-tubulin is naturally resistant to 2-Methoxyestradiol and protects patients from drug-induced myelosuppression, Cell Cycle, vol.8, issue.23, pp.3914-3938, 2009.
DOI : 10.4161/cc.8.23.10105

S. Ayral-kaloustian, N. Zhang, and C. Beyer, Cevipabulin (TTI-237): Preclinical and clinical results for a novel antimicrotubule agent, Methods and Findings in Experimental and Clinical Pharmacology, vol.31, issue.7, pp.443-450, 2009.
DOI : 10.1358/mf.2009.31.7.1415893

J. W. Landen, Noscapine Crosses the Blood-Brain Barrier and Inhibits Glioblastoma Growth, Clinical Cancer Research, vol.10, issue.15, pp.5187-201, 2004.
DOI : 10.1158/1078-0432.CCR-04-0360

S. Honore, Synergistic Suppression of Microtubule Dynamics by Discodermolide and Paclitaxel in Non-Small Cell Lung Carcinoma Cells, Cancer Research, vol.64, issue.14, pp.4957-64, 2004.
DOI : 10.1158/0008-5472.CAN-04-0693

L. A. Martello, Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines, Clin Cancer Res, vol.6, pp.1978-87, 2000.

I. Paterson, N. M. Gardner, E. Guzman, and A. E. Wright, Total synthesis and biological evaluation of potent analogues of dictyostatin: Modification of the C2???C6 dienoate region, Bioorganic & Medicinal Chemistry Letters, vol.18, issue.23, pp.6268-72, 2008.
DOI : 10.1016/j.bmcl.2008.09.109

D. Agostino and G. , A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer, International Journal of Gynecological Cancer, vol.16, issue.1, pp.71-77, 2006.
DOI : 10.1111/j.1525-1438.2006.00276.x

M. J. Edelman, Phase 2 study of cryptophycin 52 ( LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer, Lung Cancer, vol.39, issue.2, pp.197-206, 2003.
DOI : 10.1016/S0169-5002(02)00511-1

A. Canta, A. Chiorazzi, and G. Cavaletti, Tubulin: A Target for Antineoplastic Drugs into the Cancer Cells but also in the Peripheral Nervous System, Current Medicinal Chemistry, vol.16, issue.11, pp.1315-1339, 2009.
DOI : 10.2174/092986709787846488

A. A. Argyriou, M. Koltzenburg, P. Polychronopoulos, S. Papapetropoulos, and H. P. Kalofonos, Peripheral nerve damage associated with administration of taxanes in patients with cancer, Critical Reviews in Oncology/Hematology, vol.66, issue.3, pp.218-246, 2008.
DOI : 10.1016/j.critrevonc.2008.01.008

K. Kuroi and K. Shimozuma, Neurotoxicity of taxanes: Symptoms and quality of life assessment, Breast Cancer, vol.36, issue.1, pp.92-101, 2004.
DOI : 10.1007/BF02968010

J. J. Lee, Changes in Neurologic Function Tests May Predict Neurotoxicity Caused by Ixabepilone, Journal of Clinical Oncology, vol.24, issue.13, pp.2084-91, 2006.
DOI : 10.1200/JCO.2005.04.2820

N. V. Lyubimova, M. G. Toms, I. N. Shakirova, O. I. Gurina, and N. Kushlinskii, Biochemical parameters in the diagnosis and monitoring of neurotoxicity of antitumor cytostatics, Bull Exp Biol Med, vol.132, pp.1093-1098, 2001.

C. Bokemeyer, C. C. Berger, M. A. Kuczyk, and H. J. Schmoll, Evaluation of long-term toxicity after chemotherapy for testicular cancer., Journal of Clinical Oncology, vol.14, issue.11, pp.2923-2955, 1996.
DOI : 10.1200/JCO.1996.14.11.2923

D. Schiff, P. Y. Wen, and M. J. Van-den-bent, Neurological adverse effects caused by cytotoxic and targeted therapies, Nature Reviews Clinical Oncology, vol.141, issue.10, pp.596-603, 2009.
DOI : 10.1038/nrclinonc.2009.128

M. S. Poruchynsky, Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: A possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition, Cell Cycle, vol.7, issue.7, pp.940-949, 2008.
DOI : 10.4161/cc.7.7.5625

J. L. Anderl, S. Redpath, and A. J. Ball, A Neuronal and Astrocyte Co-Culture Assay for High Content Analysis of Neurotoxicity, Journal of Visualized Experiments, vol.27, issue.27, pp.10-3791, 2009.
DOI : 10.3791/1173

N. Authier, Animal models of chemotherapy-evoked painful peripheral neuropathies, Neurotherapeutics, vol.58, issue.4, pp.620-629, 2009.
DOI : 10.1016/j.nurt.2009.07.003

R. E. Davis, B. E. Schlumpf, and P. Klinger, Comparative neurotoxicity of tubulin-binding drugs: Inhibition of goldfish optic nerve regeneration, Toxicology and Applied Pharmacology, vol.80, issue.2, pp.308-323, 1985.
DOI : 10.1016/0041-008X(85)90088-2

C. Y. Fan, J. Cowden, S. O. Simmons, S. Padilla, and R. Ramabhadran, Gene expression changes in developing zebrafish as potential markers for rapid developmental neurotoxicity screening, Neurotoxicology and Teratology, vol.32, issue.1, 2009.
DOI : 10.1016/j.ntt.2009.04.065

B. Kiburg, C. Moorer-van-delft, J. J. Heimans, P. C. Huijgens, and H. H. Boer, In vivo modulation of vincristine-induced neurotoxicity in Lymnaea stagnalis, by the ACTH(4?9)analogue Org 2766, Journal of Neuro-Oncology, vol.30, issue.3, pp.173-80, 1996.
DOI : 10.1007/BF00177268

L. T. Vahdat, Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane, Journal of Clinical Oncology, vol.27, issue.18, pp.2954-61, 2009.
DOI : 10.1200/JCO.2008.17.7618

URL : https://hal.archives-ouvertes.fr/hal-01440451

A. Wienecke and G. Bacher, Indibulin, a Novel Microtubule Inhibitor, Discriminates between Mature Neuronal and Nonneuronal Tubulin, Cancer Research, vol.69, issue.1, pp.171-178, 2009.
DOI : 10.1158/0008-5472.CAN-08-1342

R. L. Oostendorp, Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors, Investigational New Drugs, vol.95, issue.2, pp.163-70, 2010.
DOI : 10.1007/s10637-009-9244-6

S. P. Blagden, A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours, British Journal of Cancer, vol.24, issue.5, pp.894-903, 2008.
DOI : 10.1016/S1471-4892(01)00064-9

P. A. Tang, Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck, Investigational New Drugs, vol.54, issue.3, pp.257-64, 2008.
DOI : 10.1007/s10637-007-9098-8

J. J. Knox, A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168), Investigational New Drugs, vol.43, issue.3, pp.265-72, 2008.
DOI : 10.1007/s10637-007-9103-2

T. Vats, A study of toxicity and comparative therapeutic efficacy of vindesine-prednisone vs. vincristine-prednisone in children with acute lymphoblastic leukemia in relapse, Investigational New Drugs, vol.2, issue.3, pp.231-235, 1992.
DOI : 10.1007/BF00877252

D. N. Lysitsas, Antirestenotic Effects of a Novel Polymer-Coated D-24851 Eluting Stent. Experimental Data in a Rabbit Iliac Artery Model, CardioVascular and Interventional Radiology, vol.104, issue.4, pp.1192-200, 2007.
DOI : 10.1007/s00270-007-9027-4

C. Aghajanian, Phase I Study of the Novel Epothilone Analog Ixabepilone (BMS-247550) in Patients With Advanced Solid Tumors and Lymphomas, Journal of Clinical Oncology, vol.25, issue.9, pp.1082-1090, 2007.
DOI : 10.1200/JCO.2006.08.7304

D. Bissett, Phase I and pharmacokinetic study of rhizoxin, Cancer Res, vol.52, pp.2894-2902, 1992.

C. Cunningham, Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors, Clinical Cancer Research, vol.11, issue.21, pp.7825-7858, 2005.
DOI : 10.1158/1078-0432.CCR-05-0058

P. Zatloukal, Randomized Multicenter Phase II Study of Larotaxel (XRP9881) in Combination with Cisplatin or Gemcitabine as First-Line Chemotherapy in Nonirradiable Stage IIIB or Stage IV Non-small Cell Lung Cancer, Journal of Thoracic Oncology, vol.3, issue.8, pp.894-901, 2008.
DOI : 10.1097/JTO.0b013e31817e6669

J. M. Larkin and S. B. Kaye, Epothilones in the treatment of cancer, Expert Opinion on Investigational Drugs, vol.5, issue.6, pp.691-702, 2006.
DOI : 10.1158/1078-0432.CCR-04-2019

A. Greystoke, A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours, Annals of Oncology, vol.17, issue.8, pp.1313-1322, 2006.
DOI : 10.1093/annonc/mdl097

M. Markman, Managing taxane toxicities, Support Care Cancer, vol.11, pp.144-151, 2003.

C. Swanton, Chromosomal instability determines taxane response, Proceedings of the National Academy of Sciences, vol.106, issue.21, pp.8671-8677, 2009.
DOI : 10.1073/pnas.0811835106

B. P. Bouchet, Paclitaxel resistance in untransformed human mammary epithelial cells is associated with an aneuploidy-prone phenotype, British Journal of Cancer, vol.350, issue.9, pp.1218-1242, 2007.
DOI : 10.1016/j.ccr.2006.12.003

V. K. Rao, The extent of chromosomal aberrations induced by chemotherapy in non-human primates depends on the schedule of administration, Mutation Research/Genetic Toxicology and Environmental Mutagenesis, vol.583, issue.2, pp.105-124, 2005.
DOI : 10.1016/j.mrgentox.2005.01.013

E. Hamel, D. L. Sackett, D. Vourloumis, and K. C. Nicolaou, The Coral-Derived Natural Products Eleutherobin and Sarcodictyins A and B:?? Effects on the Assembly of Purified Tubulin with and without Microtubule-Associated Proteins and Binding at the Polymer Taxoid Site, Biochemistry, vol.38, issue.17, pp.5490-5498, 1999.
DOI : 10.1021/bi983023n

S. L. Mooberry, G. Tien, A. H. Hernandez, A. Plubrukarn, and B. S. Davidson, Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents, Cancer Res, vol.59, pp.653-60, 1999.

E. J. Gapud, R. Bai, A. K. Ghosh, and E. Hamel, Laulimalide and Paclitaxel: A Comparison of Their Effects on Tubulin Assembly and Their Synergistic Action When Present Simultaneously, Molecular Pharmacology, vol.66, issue.1, pp.113-134, 2004.
DOI : 10.1124/mol.66.1.113

F. Loganzo, Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin, Mol Cancer Ther, vol.3, pp.1319-1346, 2004.

T. N. Gaitanos, Peloruside A Does Not Bind to the Taxoid Site on ??-Tubulin and Retains Its Activity in Multidrug-Resistant Cell Lines, Cancer Research, vol.64, issue.15, pp.5063-5070, 2004.
DOI : 10.1158/0008-5472.CAN-04-0771

A. L. Risinger, The Taccalonolides: Microtubule Stabilizers That Circumvent Clinically Relevant Taxane Resistance Mechanisms, Cancer Research, vol.68, issue.21, pp.8881-8889, 2008.
DOI : 10.1158/0008-5472.CAN-08-2037

C. Bailly, Synthesis and Biological Evaluation of 4-Arylcoumarin Analogues of Combretastatins, Journal of Medicinal Chemistry, vol.46, issue.25, pp.5437-5481, 2003.
DOI : 10.1021/jm030903d

R. M. Buey, Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites, Nature Chemical Biology, vol.78, issue.2, pp.117-142, 2007.
DOI : 10.1038/nchembio853

S. Mozzetti, Molecular Mechanisms of Patupilone Resistance, Cancer Research, vol.68, issue.24, pp.10197-204, 2008.
DOI : 10.1158/0008-5472.CAN-08-2091

C. Ferlini, 532 The seco-taxane idn5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance, European Journal of Cancer Supplements, vol.2, issue.8, pp.2397-405, 2005.
DOI : 10.1016/S1359-6349(04)80540-8

L. Phillips and G. D. , Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate, Cancer Research, vol.68, issue.22, pp.9280-90, 2008.
DOI : 10.1158/0008-5472.CAN-08-1776

A. M. Al-katib, A. Aboukameel, R. Mohammad, M. C. Bissery, and C. Zuany-amorim, Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's Lymphoma, Clinical Cancer Research, vol.15, issue.12, pp.4038-4083, 2009.
DOI : 10.1158/1078-0432.CCR-08-2808

M. Beeram, A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC), Journal of Clinical Oncology, vol.25, p.1042, 2007.

I. E. Krop, Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer, Journal of Clinical Oncology, vol.28, issue.16, pp.2698-704
DOI : 10.1200/JCO.2009.26.2071

S. Smith, Technology evaluation: huN901-DM1, ImmunoGen, Curr Opin Mol Ther, vol.7, pp.394-401, 2005.

M. A. Jordan and L. Wilson, Microtubules as a target for anticancer drugs, Nature Reviews Cancer, vol.4, issue.4, pp.253-65, 2004.
DOI : 10.1038/nrc1317

J. J. Stephenson, Phase I multicenter study to assess the safety, tolerability, and pharmacokinetics of AZD4877 administered twice weekly in adult patients with advanced solid malignancies, Journal of Clinical Oncology, vol.26, issue.15_suppl, p.2516, 2008.
DOI : 10.1200/jco.2008.26.15_suppl.2516

L. Pusztai, Evaluation of Microtubule-Associated Protein-Tau Expression As a Prognostic and Predictive Marker in the NSABP-B 28 Randomized Clinical Trial, Journal of Clinical Oncology, vol.27, issue.26, pp.4287-92, 2009.
DOI : 10.1200/JCO.2008.21.6887

D. C. Altieri, The case for survivin as a regulator of microtubule dynamics and cell-death decisions, Current Opinion in Cell Biology, vol.18, issue.6, pp.609-624, 2006.
DOI : 10.1016/j.ceb.2006.08.015

J. R. Cooper, M. Wagenbach, C. L. Asbury, and L. Wordeman, Catalysis of the microtubule on-rate is the major parameter regulating the depolymerase activity of MCAK, Nature Structural & Molecular Biology, vol.196, issue.1, pp.77-82, 2010.
DOI : 10.1038/45483

S. Rana, P. B. Maples, N. Senzer, and J. Nemunaitis, Stathmin 1: a novel therapeutic target for anticancer activity, Expert Review of Anticancer Therapy, vol.8, issue.9, pp.1461-70, 2008.
DOI : 10.1586/14737140.8.9.1461

L. Pusztai, Markers predicting clinical benefit in breast cancer from microtubuletargeting agents, Ann Oncol, vol.18, issue.12, pp.15-20, 2007.

P. Seve and C. Dumontet, Chemoresistance in Non-Small Cell Lung Cancer, Current Medicinal Chemistry-Anti-Cancer Agents, vol.5, issue.1, pp.73-88, 2005.
DOI : 10.2174/1568011053352604

S. Marsh, Pharmacogenetic Assessment of Toxicity and Outcome After Platinum Plus Taxane Chemotherapy in Ovarian Cancer: The Scottish Randomised Trial in Ovarian Cancer, Journal of Clinical Oncology, vol.25, issue.29, pp.4528-4563, 2007.
DOI : 10.1200/JCO.2006.10.4752

E. P. Bruggemann, S. J. Currier, M. M. Gottesman, and I. Pastan, Characterization of the azidopine and vinblastine binding site of P-glycoprotein, J Biol Chem, vol.267, pp.21020-21026, 1992.

G. K. Chen, G. E. Duran, and A. Mangili, Beketic-Oreskovic, L. & Sikic, B. I. MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES- SA cells, British Journal of Cancer, vol.83, issue.7, pp.892-900, 2000.
DOI : 10.1054/bjoc.2000.1371

S. P. Cole, Pharmacological characterization of multidrug resistant MRPtransfected human tumor cells, Cancer Res, vol.54, pp.5902-5912, 1994.

X. H. Hua, Biochemical genetic analysis of indanocine resistance in human leukemia, Cancer Res, vol.61, pp.7248-54, 2001.

M. M. Wagner, In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines, Cancer Chemotherapy and Pharmacology, vol.43, issue.2, pp.115-140, 1999.
DOI : 10.1007/s002800050871

D. L. Toppmeyer, C. A. Slapak, J. Croop, and D. W. Kufe, Role of P-glycoprotein in dolastatin 10 resistance, Biochemical Pharmacology, vol.48, issue.3, pp.609-621, 1994.
DOI : 10.1016/0006-2952(94)90292-5

T. C. Chou, Therapeutic effect against human xenograft tumors in nude mice by the third generation microtubule stabilizing epothilones, Proceedings of the National Academy of Sciences, vol.105, issue.35, pp.13157-62, 2008.
DOI : 10.1073/pnas.0804773105

J. J. Xiao, Efflux of Depsipeptide FK228 (FR901228, NSC-630176) Is Mediated by P-Glycoprotein and Multidrug Resistance-Associated Protein 1, Journal of Pharmacology and Experimental Therapeutics, vol.313, issue.1, pp.268-76, 2005.
DOI : 10.1124/jpet.104.072033

J. Gertsch, Making Epothilones Fluoresce: Design, Synthesis, and Biological Characterization of a Fluorescent N12-Aza-Epothilone (Azathilone), ChemBioChem, vol.46, issue.15, pp.2513-2534, 2009.
DOI : 10.1002/cbic.200900376

Y. Akashi, The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo, British Journal of Cancer, vol.77, issue.10, pp.1532-1541, 2007.
DOI : 10.1111/j.1349-7006.2006.00330.x

D. Simoni, Heterocyclic and Phenyl Double-Bond-Locked Combretastatin Analogues Possessing Potent Apoptosis-Inducing Activity in HL60 and in MDR Cell Lines, Journal of Medicinal Chemistry, vol.48, issue.3, pp.723-759, 2005.
DOI : 10.1021/jm049622b

M. Bayes and X. Rabasseda, Gateways to clinical trials, Methods Find Exp Clin Pharmacol, vol.30, pp.67-99, 2008.

H. Wehbe, C. M. Kearney, and K. G. Pinney, Combretastatin A-4 resistance in H460 human lung carcinoma demonstrates distinctive alterations in beta-tubulin isotype expression, Anticancer Res, vol.25, pp.3865-70, 2005.

G. Schumacher, Antineoplastic activity of 2-methoxyestradiol in human pancreatic and gastric cancer cells with different multidrug-resistant phenotypes, Journal of Gastroenterology and Hepatology, vol.65, issue.9, pp.1469-73, 2007.
DOI : 10.1158/0008-5472.CAN-05-0088

A. C. Lockhart, Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors, Cancer Chemotherapy and Pharmacology, vol.9, issue.Suppl 2, pp.203-212, 2007.
DOI : 10.1007/s00280-006-0362-y

R. K. Ramanathan, A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer, Cancer Chemotherapy and Pharmacology, vol.24, issue.3, pp.453-461, 2008.
DOI : 10.1007/s00280-007-0489-5

N. Yamamoto, N. Boku, and H. Minami, Phase I study of larotaxel administered as a 1-h intravenous infusion every 3??weeks to Japanese patients with advanced solid tumours, Cancer Chemotherapy and Pharmacology, vol.42, issue.Suppl 5, pp.129-165, 2009.
DOI : 10.1007/s00280-009-1014-9

V. Dieras, Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy, Annals of Oncology, vol.19, issue.7
DOI : 10.1093/annonc/mdn060

O. Metzger-filho, C. Moulin, E. De-azambuja, and A. Ahmad, Larotaxel: broadening the road with new taxanes, Expert Opinion on Investigational Drugs, vol.18, issue.8, pp.1183-1192, 2009.
DOI : 10.1080/02841860500486630

M. Beer, L. Lenaz, and D. Amadori, Phase II study of ortataxel in taxane-resistant breast cancer, Journal of Clinical Oncology, vol.26, issue.15_suppl, p.1066, 2008.
DOI : 10.1200/jco.2008.26.15_suppl.1066

J. Rhee, F. Lee, and M. Saif, Phase II trial of DJ-927 as a second-line treatment for colorectal cancer demonstrates objective responses, Journal of Clinical Oncology, vol.23, issue.16_suppl, p.3654, 2005.
DOI : 10.1200/jco.2005.23.16_suppl.3654

P. Baas, Phase I/II Study of a 3 Weekly Oral Taxane (DJ-927) in Patients with Recurrent, Advanced Non-small Cell Lung Cancer, Journal of Thoracic Oncology, vol.3, issue.7, pp.745-50, 2008.
DOI : 10.1097/JTO.0b013e31817c73ff

S. R. Patel, Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas, Investigational New Drugs, vol.16, issue.1, pp.87-92, 1998.
DOI : 10.1023/A:1006078930550

R. Pazdur, Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity

I. Judson, Phase I trial and pharmacokinetics of the tubulin inhibitor 1069C85--a synthetic agent binding at the colchicine site designed to overcome multidrug resistance, British Journal of Cancer, vol.75, issue.4, pp.608-621, 1997.
DOI : 10.1038/bjc.1997.107

K. Yamamoto, Phase I study of E7010, Cancer Chemotherapy and Pharmacology, vol.42, issue.2, pp.127-161, 1998.
DOI : 10.1007/s002800050795

I. E. Kuppens, Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors, Investigational New Drugs, vol.1, issue.3, pp.227-262, 2007.
DOI : 10.1007/s10637-006-9027-2